MDNews - Lower Hudson/Bronx

May 2013

Issue link: https://viewer.e-digitaledition.com/i/125960

Contents of this Issue

Navigation

Page 5 of 43

COVER FEATURE A Multifaceted Approach to Treating Melanoma at Montefiore Einstein Center for Cancer Care AT MONTEFIORE EINSTEIN Center for Cancer Care, a multidisciplinary team of medical, surgical and radiation oncologists, as well as dermatologists, collaborates with nutritionists, pathologists, palliative care providers, plastic surgeons, nuclear medicine specialists and social workers to provide customized treatment plans that meet the comprehensive needs of each patient who enters the Melanoma/Sarcoma Program. After the group identifies the most appropriate treatment path, a specialist from medical, surgical or radiation oncology — whichever is appropriate — takes over as the patient's lead physician, with experts from the group contributing as necessary. Stuart Packer, M.D., examines a patient. 6 | Lower Hudson/Bronx MD NEWS I MDNEWS.COM Targeted Medical Treatments St ua r t Packer, M.D., Clin ica l Director, Weiler Oncology Service and Director, Melanoma/Sarcoma Program, Montefiore Einstein Center for Cancer Care, and assistant professor, Department of Medicine (Oncology), Albert Einstein College of Medicine, takes the lead when the team deems medical management the most appropriate course of treatment for a patient. The partnership between Montefiore Medical Center and Albert Einstein College of Medicine enables Dr. Packer and the team to provide both traditional treatments, such as interferon and chemotherapy, and innovative targeted therapies and immunotherapies that only an experienced team can offer because of associated side effects and specific administration guidelines. A wide variety of clinical trials and experimental treatment modalities are available as well. "One capability that makes us unique is that we have continued our program of IL-2 [interleukin-2], which has been around since the early 1990s," Dr. Packer explains. "Because this therapy requires specialized techniques and care, not many institutions provide it." The United States Food and Drug Administration (FDA) approved IL-2 in 1992 after clinical trials — in which Montefiore Einstein Center for Cancer Care participated — demonstrated the drug's efficacy. IL-2 is the only therapy recognized as producing durable remissions, and some patients have even experienced remissions lasting more than 20 years, according to Dr. Packer. The Montefiore team is experienced and equipped to offer high-dose IL-2 and address its potential side effects, such as capillary leak syndrome, chills, fever and low blood pressure. "Albert Einstein College of Medicine was part of the original IL-2 trials, and we have made a recommitment to use IL-2," Dr. Packer says. "It's one option for treatment, and we felt that, being a multidisciplinary, full-service, tertiary care center, it was necessary to offer its benefits to appropriate patients." Commonly administered intravenously for 15 minutes every eight hours, IL-2 treatment takes place in two or three five-day courses separated by a seven- to 10-day rest period. IL-2 activates the immune system's T-lymphocyte (T-cell) response to stave off or slow cancer cell growth in patients with stage 4 metastatic melanoma. Dr. Packer explains that exclusion PHOTOS © DON DEMPSEY, WHITE LIGHT PHOTOGRAPHY MONTEFIORE EINSTEIN CENTER FOR CANCER CARE'S MELANOMA/SARCOMA PROGRAM OFFERS LEADING-EDGE TREATMENTS FOR THE MOST DEADLY FORM OF SKIN CANCER.

Articles in this issue

Links on this page

Archives of this issue

view archives of MDNews - Lower Hudson/Bronx - May 2013